ライフサイエンスコーパス: adverse drug event

1 ial resistance can often be thought of as an adverse drug event.

2 European Consortium (PROTECT) checklist for adverse drug events.

3 nd environmental factors, drug responses and adverse drug events.

4 ts were the most common types of preventable adverse drug events.

5 ared with 177 (18.7%) of the 945 significant adverse drug events.

6 ation categories associated with preventable adverse drug events.

7 in 1.8% (95% CI, 1.5%-2.1%) of ED visits for adverse drug events.

8 ultiple types of medications, which can have adverse drug events.

9 medications (PIMs), which in turn may reduce adverse drug events.

10 uce treatment burden, costs, and the risk of adverse drug events.

11 ions (DDIs) are a major cause of preventable adverse drug events.

12 s represent one of the most popular types of adverse drug events.

13 risk substantially by raising the chances of adverse drug events.

14 ausally linked to both treatment success and adverse drug events.

15 s focusing on addiction and PCPs focusing on adverse drug events.

16 D visits and subsequent hospitalizations for adverse drug events.

17 n inappropriate antibiotic prescriptions and adverse drug events.

18 iation between inappropriate antibiotics and adverse drug events.

19 cluded data on time to adequate sedation and adverse drug events.

20 risk factors of infectious and noninfectious adverse drug events.

21 ked composite of mortality, readmission, and adverse drug events.

22 d for rescue medication, symptom relief, and adverse drug events.

23 1.5-fold higher risk for clinically relevant adverse drug events.

24 is very expensive and often associated with adverse drug events.

25 ug interactions (DDIs) are a common cause of adverse drug events.

26 7 cases, there was a total of 499 documented adverse drug events.

27 trum antibiotic use, treatment failures, and adverse drug events.

28 ied those that could be harmful as potential adverse drug events.

29 for our patients and, in particular, reduce adverse drug events.

30 mps to critically ill patients can result in adverse drug events.

31 rs included both near-misses and preventable adverse drug events.

32 ncidence and nature of medication errors and adverse drug events.

33 survey (response rate, 55 percent), 162 had adverse drug events (25 percent; 95 percent confidence i

34 59.9% (95% CI, 56.8%-62.9%) of ED visits for adverse drug events; 4 anticoagulants (warfarin, rivarox

35 ic treatment, 75 and 42), had frequent minor adverse drug events (53% and 55%), reported significant

36 Of the adverse drug events, 578 (38.0%) were categorized as ser

37 Adverse drug events accounted for 2.5% (95% CI, 2.0%-3.1

38 atements pertaining to medication errors and adverse drug events addressing the key components.

39 Drug-drug interaction-induced (DDI-induced) adverse drug event (ADE) is a significant public health

40 The National Action Plan for Adverse Drug Event (ADE) Prevention identified 3 high-pr

41 , missing, or uncharacterized in spontaneous adverse drug event (ADE) reporting systems.

42 Adverse drug events (ADEs) are a significant and costly

43 Adverse drug events (ADEs) are the most common type of i

44 We compared the risk of adverse drug events (ADEs) associated with antibiotic re

45 Adverse drug events (ADEs) constitute one of the leading

46 ill patients are particularly susceptible to adverse drug events (ADEs) due to their rapidly changing

47 spite their topical administration, systemic adverse drug Events (ADEs) have been reported.

48 re, we evaluated the occurrence of pulmonary adverse drug events (ADEs) in patients with hypertension

49 Under-reporting of adverse drug events (ADEs) is a challenge facing develop

50 Drug adverse events (AEs), or called adverse drug events (ADEs), are ranked one of the leadin

51 They include preventable or ameliorable adverse drug events (ADEs), as well as medication discre

52 Given that older adults are at high risk for adverse drug events (ADEs), many geriatric medication pr

53 te the impact that deprescribing may have on adverse drug events (ADEs).

54 imates of the real-world burden of clozapine adverse drug events (ADEs).

55 ence has shown that sex differences exist in Adverse Drug Events (ADEs).

56 Adverse drugs events (ADEs) detection constitutes a cons

57 [aHR] 2.77, 95% CI 1.2-6.66) and any serious adverse drug event (aHR 4.28, 95% CI 1.88-9.71).

58 dication administration as well as potential adverse drug events, although it did not eliminate such

59 Adverse drug events among outpatients that lead to emerg

60 However, few data are available on adverse drug events among outpatients.

61 .0% (95% CI, 0.6%-1.4%) of ED visits for all adverse drug events among patients>/=40 years, but an es

62 % CI, 4.0%-7.9%) of hospitalizations for all adverse drug events among patients>/=85 years.

63 hose individuals involved in the preventable adverse drug event and potential adverse drug event unde

64 tion errors, including 14 and 11 preventable adverse drug events and 73 and 82 nonintercepted potenti

65 s are also well-established risk factors for adverse drug events and antibiotic-resistant infections

66 represented adverse drug events or potential adverse drug events and as to severity and preventabilit

67 We aimed to estimate the comparative risk of adverse drug events and attributable healthcare expendit

68 ommon and associated with increased risks of adverse drug events and higher attributable health care

69 ss, they tend to overlook the possibility of adverse drug events and medication errors in their diffe

70 tive prescribing has the potential to reduce adverse drug events and patient harm and cost; however,

71 The rate of preventable adverse drug events and potential adverse drug events in

72 Preventable adverse drug events and potential adverse drug events oc

73 re was no greater likelihood for preventable adverse drug events and potential adverse drug events to

74 Rate of preventable adverse drug events and potential adverse drug events, l

75 were associated with higher risk of several adverse drug events and potential microbiome-related adv

76 The risks of adverse drug events and potential microbiome-related eve

77 eal-time or near real-time identification of adverse drug events and potentially afford the practitio

78 ctor for prescribing and adherence problems, adverse drug events, and other adverse health outcomes.

79 rough optimization of drug use, avoidance of adverse drug events, and transitional care activities fo

80 e likely than younger individuals to sustain adverse drug events (annual estimate, 4.9 vs 2.0 per 100

81 elderly persons with age-related conditions, adverse drug events are an important cause of illness an

82 Adverse drug events are common and often preventable amo

83 Adverse drug events are common and often preventable cau

84 Adverse drug events are common in the intensive care uni

85 Adverse drug events are important preventable causes of

86 More serious adverse drug events are more likely to be preventable.

87 nd rationale for meaningful documentation of adverse drug events are provided, along with an outline

88 y 27.3% (P<0.001), but the rate of potential adverse drug events associated with timing errors did no

89 rated importance of pain relief relative to adverse drug event avoidance), preferred treatment thres

90 s is an essential step to reduce the risk of adverse drug events before clinical drug co-prescription

91 re unit teams, and patients involved in each adverse drug event by comparing ICUs with non-ICUs and m

92 The costs of an adverse drug event can be substantial to healthcare syst

93 d, nationally representative data describing adverse drug events can help focus these efforts.

94 The clinical outcomes of adverse drug events can result in end-organ damage and e

95 Over the 2-year study period, 21,298 adverse drug event cases were reported, producing weight

96 Adverse drug events cause substantial morbidity and mort

97 ated with a reduction in the monthly rate of adverse drug events (coefficient = -0.021; 95% CI, -0.03

98 ommon in older adults and is associated with adverse drug events, cognitive and functional impairment

99 o polypharmacy could lead to improvements in adverse drug events, cost, and possibly quality of life.

100 l different methods are available for robust adverse drug event data collection, such as target chart

101 Aggregation of adverse drug event data has evolved in the last decade.

102 Antibiotic-associated adverse drug events decreased by 30%.

103 Continued development of adverse drug event detection will allow for further qual

104 t onset of drug-induced injury, known as an "adverse drug event." Drug-induced episodes were evaluate

105 No patients had serious adverse drug events during treatment and no patients sto

106 Adverse drug events (eg, anaphylaxis), incidence of mild

107 Disorders of coagulation are common adverse drug events encountered in critically ill patien

108 ol in ensuring patient safety and decreasing adverse drug events, especially for complex patients and

109 Adverse drug events, especially those that may be preven

110 31.8%; 95% CI, 28.7%-34.9%) in ED visits for adverse drug events, followed by antipsychotics (4.5%; 9

111 edications had a 3% higher risk of having an adverse drug event for each drug dispensed.

112 Critically ill patients are at high risk for adverse drug events for many reasons, including the comp

113 rities and disproportionately lead to costly adverse drug events for some groups.

114 2005-2006, the proportions of ED visits for adverse drug events from anticoagulants and diabetes age

115 Extraction of adverse drug events from biomedical literature and other

116 Although adverse drug events have been extensively evaluated by c

117 21 measures across 4 adverse event domains: adverse drug events, hospital-acquired infections, adver

118 ined significantly in all patient groups for adverse drug events, hospital-acquired infections, and g

119 ia: 1 in which the medication could cause an adverse drug event if continued and the other in which t

120 esults may facilitate the early diagnosis of adverse drug events in clinical application.

121 inal study was to determine risk factors for adverse drug events in critically ill adult patients.

122 An evaluation of risk factors for adverse drug events in critically ill patients has not b

123 ported with many drugs, and these are common adverse drug events in critically ill patients that can

124 ed characteristics contribute to the risk of adverse drug events in critically ill patients.

125 ant factor that contributes significantly to adverse drug events in current healthcare practice.

126 reventable adverse drug events and potential adverse drug events in ICUs was 19 events per 1000 patie

127 rdable Care Act of 2010 brought attention to adverse drug events in national patient safety efforts.

128 zation after emergency department visits for adverse drug events in older adults and to assess the co

129 st emergency hospitalizations for recognized adverse drug events in older adults resulted from a few

130 the potential to reduce hospitalizations for adverse drug events in older adults.

131 vents and 73 and 82 nonintercepted potential adverse drug events in the control and intervention peri

132 tics of emergency department (ED) visits for adverse drug events in the United States in 2013-2014 an

133 revalence of emergency department visits for adverse drug events in the United States was estimated t

134 idence interval [CI], 55,531 to 143,724) for adverse drug events in U.S. adults 65 years of age or ol

135 ) was associated with higher risk of several adverse drug events including hypersensitivity reaction

136 re associated with increased risk of several adverse drug events, including Clostridioides difficile

137 re associated with increased risk of several adverse drug events, including Clostridioides difficile

138 nd risks for emergency department visits for adverse drug events involving Beers criteria medications

139 lly representative information on outpatient adverse drug events is limited.

140 reventable adverse drug events and potential adverse drug events, length of stay, charges, costs, and

141 uch as adverse event, adverse drug reaction, adverse drug event, medication error, and side effect.

142 les from infectious disease surveillance and adverse drug event monitoring demonstrate that the techn

143 gical procedures (n=292, 49.3%), followed by adverse drug events (n=158, 26.6%), healthcare associate

144 nts related to medication therapy, including adverse drug events, nonadherence, and clinical outcomes

145 34.5% (95% CI, 30.3%-38.8%) of ED visits for adverse drug events occurred among adults aged 65 years

146 sits (95% CI, 100,155 to 254,854 visits) for adverse drug events occurred both years.

147 Adverse drug events occurred in 258 patients (30.3%) and

148 reventable adverse drug events and potential adverse drug events occurred in units that functioned no

149 Errors associated with preventable adverse drug events occurred most often at the stages of

150 stimated 4.0 (95% CI, 3.1-5.0) ED visits for adverse drug events occurred per 1000 individuals annual

151 There were 1523 identified adverse drug events, of which 27.6% (421) were considere

152 Patients were also encouraged to report adverse drug events on the videos.

153 ent reviewers as to whether they represented adverse drug events or potential adverse drug events and

154 The rate of potential adverse drug events (other than those associated with ti

155 condary outcomes include all-cause death and adverse drug events over 1 year.

156 Clinical outcomes included rates of adverse drug events, patterns of antimicrobial resistanc

157 erson-years, with a rate of 13.8 preventable adverse drug events per 1000 person-years.

158 Adverse drug event rates were similar between the interv

159 The objective of this article is to describe adverse drug events related to the liver and gastrointes

160 critically ill patients are associated with adverse drug events related to the liver and gastrointes

161 N, including fatal cases, using the Japanese Adverse Drug Event Report database (JADER).

162 aper will review the most common and serious adverse drug events reported to occur with the use of se

163 States Food and Drug Administration (USFDA) Adverse Drug Event Reporting System (AERS) database.

164 Adverse drug events represent a key challenge in public

165 3-times, and 2-times more likely to have an adverse drug event, respectively.

166 27.3% (95% CI, 22.2%-32.4%) of ED visits for adverse drug events resulted in hospitalization.

167 ximization of drug efficacy and reduction of adverse drug event risk.

168 Number of adverse drug events, severity of the events (classified

169 th prescribing errors, risk to patients from adverse drug events should be reduced.

170 3-2014 and describe changes in ED visits for adverse drug events since 2005-2006.

171 ronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance project (2007 through 20

172 ronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance project and the National

173 ronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance Project from 2017 throug

174 ronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance project.

175 ronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance project.

176 i.e., scenarios presenting variable pain and adverse drug event symptoms in a child).

177 ts would withhold the prescribed opioid when adverse drug event symptoms were present together with h

178 The critically ill are more susceptible to adverse drug events than nonintensive care unit patients

179 However, nationally representative data on adverse drug events that result in hospitalization in th

180 es the case study of a patient with multiple adverse drug events to clarify key terms, such as advers

181 reventable adverse drug events and potential adverse drug events to occur in ICUs than in non-ICUs.

182 n level at which they would give an opioid), adverse drug event understanding, and hypothetical trade

183 preventable adverse drug event and potential adverse drug event underwent detailed interviews by peer

184 The overall rate of adverse drug events was 50.1 per 1000 person-years, with

185 11.8% after EBT (P < .0001), and the rate of adverse drug events was 8.4% after DBT and 7.2% after EB

186 The rate of preventable and potential adverse drug events was twice as high in ICUs compared w

187 acuity, length of stay, and severity of the adverse drug event were greater in ICUs than non-ICUs, b

188 Intravenous medication errors and adverse drug events were frequent and could be detected

189 Potential adverse drug events were identified in 38 treated patien

190 ay (7.0 pre-AXDX vs 6.5 days post-AXDX), and adverse drug events were not significantly different bet

191 dication classes most frequently involved in adverse drug events were selective serotonin-reuptake in

192 Adverse drug events were the most common adverse events

193 46.9% (95% CI, 44.2%-49.7%) of ED visits for adverse drug events, which included clinically significa

194 MREs included adverse drug events with or without misuse and medicatio